NEW
YORK, July 25, 2024 /PRNewswire/ -- NYU Langone
Health's Perlmutter Cancer Center has named Jonathan M. Gerber, MD, as its new chief
clinical officer. Dr. Gerber joins NYU Langone from the
University of Massachusetts Chan
Medical School and UMass Memorial Health, where he served as the
director of the cancer center and chief of hematology and
oncology.
In his new role, Dr. Gerber will work with Perlmutter Cancer
Center (PCC) and NYU Langone leadership teams to establish and
ensure the highest quality of cutting-edge patient care, effective
collaboration among faculty and staff, and the integration of
clinical and translational research at PCC locations in
Manhattan, Brooklyn, Queens, and Long
Island. He will also coordinate efforts across different
cancer specialties, departments, and campuses.
"I'm thrilled to be joining the Perlmutter Cancer Center as it
continues to grow and evolve," says Dr. Gerber. "I look forward to
working with colleagues across NYU Langone Health to expand and
innovate the world-class care at each of our locations."
Dr. Gerber's clinical interests include leukemia and related
hematologic conditions, as well as blood and marrow transplantation
(BMT) and cellular therapy. He is also a translational laboratory
researcher and an early-phase clinical trial investigator. His
research focuses on improving the identification and targeting of
the stem cells at the root of leukemia and other hematologic
diseases, with the goal of personalizing therapy and developing
treatments that are more effective and less toxic.
"Dr. Gerber is a proven leader in the world of cancer care and
research," says Alec Kimmelman, MD,
PhD, the Anita Steckler and Joseph Steckler Chair of Radiation
Oncology, and the director of the Perlmutter Cancer Center at NYU
Langone Health. "We are fortunate to have him join our team to lead
our clinical efforts and to ensure all of our patients have access
to our outstanding care and state-of-the-art clinical trials."
About Dr. Gerber
Dr. Gerber received his BA in biology and MD at Johns Hopkins, where he also completed his internal
medicine residency and hematology fellowship. Upon completion of
his training, he served on the faculty of the Johns Hopkins School of Medicine and Johns Hopkins
Hospital for five years in the Division of Hematology. From there,
he joined the Levine Cancer Institute (LCI) as the founding
director of its Leukemia Division. While at LCI, he helped launch
the BMT Program, performing the first allogeneic BMT in an adult in
Charlotte, NC, in 2014. In 2018,
he was then recruited to be the chief of hematology and oncology
and medical director of the cancer service line at the University of Massachusetts Chan Medical School and
UMass Memorial Health, where he was subsequently promoted to the
director of the cancer center.
Dr. Gerber has co-authored over 50 articles in prominent
publications and has presented research findings at national and
international conferences, as well as serving as a reviewer for the
National Institutes of Health and top journals in the field. He is
also a member of the editorial board and the associate editor for
hematology content for HemOnc Today. Dr. Gerber was a member
of the team that received a 2023 Top 10 Clinical Research
Achievement Award from the Clinical Research Forum for its work on
the treatment of COVID-19 with convalescent plasma, which was
published in The New England Journal of Medicine. His
leukemia research has resulted in three US patents and has been
translated into clinical trials.
Dr. Gerber is also an active member of several professional
societies, including the American Society of Hematology (ASH) and
the American Society of Clinical Oncology (ASCO). Currently, he is
a member of the ASH Committee on Practice and the liaison to the
ASH Subcommittee on Precision Medicine, as a well as a member of
the ASH Continuing Certification Working Group. He previously
served on the ASCO Cancer Research and Education committees. Dr.
Gerber has also served on the boards of the Charlotte and the New England chapters of the
Leukemia & Lymphoma Society. In addition, he was a member of
the Massachusetts Department of Public Health's Diagnosis and
Treatment Working Group for the 2024-2029 State Cancer Plan.
Media Contact:
Ryan
Dziuba
Media Relations Manager
ryan.dziuba@nyulangone.org
212-404-4131
View original content to download
multimedia:https://www.prnewswire.com/news-releases/renowned-leukemia-researcher-and-clinician-joins-nyu-langone-healths-perlmutter-cancer-center-as-new-chief-clinical-officer-302206134.html
SOURCE NYU Langone Health